Journal
ONCOLOGY REPORTS
Volume 29, Issue 4, Pages 1637-1644Publisher
SPANDIDOS PUBL LTD
DOI: 10.3892/or.2013.2285
Keywords
pancreatic cancer; ABO; genetic susceptibility; cancer risk
Categories
Funding
- Cancer Research UK [15957, 14136] Funding Source: researchfish
- Medical Research Council [G0401527, G1000143] Funding Source: researchfish
- National Institute for Health Research [NF-SI-0510-10126, NF-SI-0512-10114] Funding Source: researchfish
- Pancreatic Cancer UK [2013 RIF - Greenhalf] Funding Source: researchfish
- Cancer Research UK [14136] Funding Source: Medline
- Medical Research Council [G0401527, G1000143] Funding Source: Medline
Ask authors/readers for more resources
There is strong epidemiologic evidence indicating that common genetic variability could be implicated in pancreatic cancer risk and, to date, various loci have been proposed. In particular, there is increasing evidence of the involvement of ABO gene variability and pancreatic cancer risk. In a large multicentric study of 1,028 pancreatic ductal adenocarcinoma cases and 2,257 controls in the context of the PANcreatic Disease ReseArch (PANDoRA) consortium, we investigated the suggested association with increased risk for carriers of single nucleotide polymorphisms (SNPs) determining the A or B allele in comparison with the 0 allele, which encodes for a non-functional enzyme. Since glycosyltransferase activity, encoded by ABO, is higher for the A1 variant compared with the A2 variant, we investigated the hypothesis that A1 carriers were at an increased risk of pancreatic cancer. In our analysis, carriers of the A1 were indeed at greater risk of developing the disease. In addition, we investigated the possible influence that genetic variability at the ABO locus may have in pancreatic cancer survival, but we observed no effect in our population.
Authors
I am an author on this paper
Click your name to claim this paper and add it to your profile.
Reviews
Recommended
No Data Available